title: Prospective Longitudinal Quality of Life Assessment in Patients With Neuroendocrine Tumor Liver Metastases Treated With 90Y Radioembolization.
abstract: OBJECTIVE
  To determine the effect of Y radioembolization therapy on health-related quality of life (HRQOL) in patients with neuroendocrine tumor liver metastases (NETLM) in a prospective longitudinal study.
  
  
  METHODS
  Baseline Short-Form 36 HRQOL scores were evaluated for significant change (P < 0.05) within the total patient population at 1, 3, 6, 12, and 24 months following Y using paired t-test. Overall survival (OS) times were calculated from first Y using the Kaplan-Meier method and analyzed using the log-rank test.
  
  
  RESULTS
  Thirty patients were enrolled. There were no significant differences in any of the eight HRQOL domains when comparing baseline scores to 1, 3, or 24-month follow-up scores. At 6- and 12-month follow-up, mean mental health and social functioning domain scores were significantly higher than baseline, respectively (P = 0.007; P = 0.019). The remainder of domains showed no significant difference at 6 or 12 months. Patients with baseline Mental Component Summary (MCS) over 50.0 had significantly longer mean survival than those under 50.0 (37.50 vs. 18.19 months, P = 0.0263). Patients with baseline Physical Component Summary (PCS) over 50.0 had no significant difference in survival compared to those under 50.0 (38.09 vs. 30.69 months, P = 0.783).
  
  
  CONCLUSIONS
  Patients with NETLM treated with Y have sustained HRQOL for up to 24 months following treatment. Temporary increases in mental health and social functioning at medium-term follow-up were observed. Patients with baseline MCS scores above the normalized U.S. population had longer overall survival compared to patients with baseline scores below the normalized U.S.
  
  
  METHODS
authors.affiliation: From the *Interventional Radiology and Image-guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA; †Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven; and ‡Yale Cancer Center, New Haven, CT.
authors.forename: Brandon
authors.initials: B
authors.lastname: Cramer
authors.forename: Minzhi
authors.initials: M
authors.lastname: Xing
authors.forename: Hyun S
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D004621:Embolization, Therapeutic / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D011446:Prospective Studies; D011788:Quality of Life; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes